



NEOGENOMICS, INC PRESS RELEASE

FOR IMMEDIATE RELEASE

NeoGenomics Schedules its Q2 2010 Earnings Release for July 29, 2010

Ft. Myers, Florida – July 22, 2010 – NeoGenomics, Inc. (NASD OTC BB: NGNM) announced today that it plans to release its second quarter 2010 financial results on Thursday, July 29, 2010.

The Company has scheduled a web-cast and conference call to discuss their Q2 2010 results on July 29, 2010, at 11:00 AM EST. Interested investors should dial (877) 407-9210 (domestic) and (201) 689-8049 (international) at least five minutes prior to the call. A replay of the conference call will be available until 11:59 PM on August 6, 2010 and can be accessed by dialing (877) 660-6853 (domestic) and (201) 612-7415 (international). The playback account number is 354290 and the playback conference ID Number/PIN Number is 286. The web-cast may be accessed under the Investor Relations section of our website at <http://www.neogenomics.com> or <http://www.investorcalendar.com/IC/CEPage.asp?ID=160682>. An archive of the web-cast will be available until 11:59 PM EST on October 29, 2010.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, clinicians and hospitals throughout the United States. For additional information about NeoGenomics, visit <http://www.neogenomics.org>.

For more news and information on NeoGenomics, please visit www.IRGnews.com/coi/NGNM where you can find a fact sheet on the company, investor presentations, and more. Interested parties can also access additional investor relations material, including an investment profile and an equity research report, from Hawk Associates at <http://www.hawkassociates.com> or from the American Microcap Institute at <http://www.americanmicrocapinstitute.com/ngnm/>.

Forward Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.

For further information, please contact:

NeoGenomics, Inc.

Steven C. Jones
Director of Investor Relations
(239) 325-2001
sjones@neogenomics.org

Hawk Associates, Inc.

Ms. Julie Marshall
(305)-451-1888
neogenomics@hawkassociates.com

The Investor Relations Group

Investor Relations:

Rachel Colgate
(212) 825-3210
rcolgate@investorrelationsgroup.com

or

Media Relations:

Janet Vasquez
(212) 825-3210
jvasquez@investorrelationsgroup.com